Literature DB >> 9337076

Studies on adaptation to adriamycin in cells pretreated with hydrogen peroxide.

E L Anuszewska1, B M Gruber, J H Koziorowska.   

Abstract

Various investigations have reported the occurrence in bacterial and mammalian cells of an adaptive response to the toxic effects of oxidants or agents that cause oxidation via redox reactions. In our previous study, it was shown that several cell lines pretreated with a low dose of hydrogen peroxide (H2O2) exhibited an adaptive response to subsequent high doses of adriamycin (ADR), whereas other cell lines did not. Based on the observation that the cell lines utilized differed in their sensitivity towards adriamycin, we undertook the present investigation with the goal of evaluating possible relationships between the levels of antioxidant enzymes and sensitivity towards adriamycin. Another aim was to determine relationships between the inducibility of these enzymes and the occurrence of adaptation. We utilized African Green monkey kidney (V3), human embryo (CLV98), human melanoma (ME18), and Chinese hamster ovary (CHO) cell lines and experimentally developed adriamycin-resistant human melanoma (ME18/RN) and Chinese hamster ovary (CHO/RN) cell sublines. Cytotoxicity was measured by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay and trypan blue exclusion. The levels of catalase (CAT), superoxide dismutase (SOD), and glutathione peroxidase (GPx) were determined in the same kind of experiment as that revealing the occurrence of adaptation. The rank order established for catalase activities was similar to that for sensitivity towards adriamycin. Aberrant increases in the tested enzymes were demonstrated in experimental groups of all kinds of cells. We conclude that in our cell systems catalase is a major determinant of adriamycin resistance. Whether the occurrence of the adaptive response under study is dependent on the contribution of catalase, itself dependent on the degree of resistance to the drug, is discussed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9337076     DOI: 10.1016/s0006-2952(97)00206-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  5 in total

1.  Modulation of cell death in human colorectal and breast cancer cells through a manganese chelate by involving GSH with intracellular p53 status.

Authors:  Kaushik Banerjee; Satyajit Das; Saikat Majumder; Subrata Majumdar; Jaydip Biswas; Soumitra Kumar Choudhuri
Journal:  Mol Cell Biochem       Date:  2016-12-23       Impact factor: 3.396

2.  A novel copper complex induces ROS generation in doxorubicin resistant Ehrlich ascitis carcinoma cells and increases activity of antioxidant enzymes in vital organs in vivo.

Authors:  Ananda Mookerjee; Jayati Mookerjee Basu; Surajit Majumder; Shilpak Chatterjee; Gouri S Panda; Pranabananda Dutta; Smarajit Pal; Pratima Mukherjee; Thomas Efferth; Syamal Roy; Soumitra K Choudhuri
Journal:  BMC Cancer       Date:  2006-11-15       Impact factor: 4.430

3.  Effect of structural modification at the 4, 3', and 2' positions of doxorubicin on topoisomerase II poisoning, apoptosis, and cytotoxicity in human melanoma cells.

Authors:  Beata M Gruber; Elzbieta L Anuszewska; Irena Bubko; Aneta Goździk; Izabela Fokt; Waldemar Priebe
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2007-06-08       Impact factor: 4.291

4.  Development of New PCR Assay with SYBR Green I for Detection of Mycoplasma, Acholeplasma, and Ureaplasma sp. in Cell Cultures.

Authors:  Jolanta Krzysztoń-Russjan; Jakub Chudziak; Małgorzata Bednarek; Elżbieta Lidia Anuszewska
Journal:  Diagnostics (Basel)       Date:  2021-05-14

5.  Biologically active constituents from Salix viminalis bio-oil and their protective activity against hydrogen peroxide-induced oxidative stress in Chinese hamster ovary cells.

Authors:  Anna Ilnicka; Katarzyna Roszek; Andrzej Olejniczak; Michal Komoszynski; Jerzy P Lukaszewicz
Journal:  Appl Biochem Biotechnol       Date:  2014-08-30       Impact factor: 2.926

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.